Organon & Co. 的收益预期不及预期，但其股票在“持有”评级中开盘上涨。 Organon & Co. missed earnings expectations, yet its stock opened higher amid a "Hold" rating.

一家制药公司Organ & Co.报告季度收入为每股0.83美元,低于分析师预期的0.92美元。 Organon & Co., a pharmaceutical company, reported quarterly earnings of $0.83 per share, falling short of analysts' expectations of $0.92. 该公司的重点是妇女健康和生物类同,其市场上限约为40亿美元,分析家的“稳住”评级为21.33美元,目标价格为21.33美元。 The company, which focuses on women's health and biosimilars, has a market cap of about $4 billion and a "Hold" rating from analysts with a target price of $21.33. 尽管收入目标缺失,但股票呈现出正差距,其开放量高于先前的关闭量。 Despite missing earnings targets, the stock showed a positive gap up, opening higher than its previous close.